Objective To examine the relation between annual trends in the antimicrobial susceptibility of Pseudomonas aeruginosa and drug usage, we compared annual changes in the susceptibility rates of P. aeruginosa clinical isolates during a 4-year period and annual trends in the overall usage of antimicrobials during the same period. Methods We studied annual trends in MIC90/MIC50, antimicrobial use density (AUD), and antimicrobial susceptibility rates based on clinical breakpoints for 150 strains of P. aeruginosa isolated from respiratory speci- decreased (25.7, 23.7, 10.9, and 12.5). Conclusion The decrease in the AUDs of carbapenems was associated with increased susceptibility rates of P. aeruginosa to carbapenem derivatives. A continuous understanding of trends in the resistance of P. aeruginosa and various other pathogens is essential for designing countermeasures against nosocomial infections, including the proper and effective use of antimicrobials.
many antimicrobials because of its low outer-membrane permeability. Recently, multidrug-resistant P. aeruginosa strains have emerged and are now frequently isolated clinically; nosocomial infections due to resistant strains have become an important problem (3) (4) (5) . The high use of broad-spectrum antimicrobials such as carbapenems has contributed to the emergence of resistant strains of P. aeruginosa (6, 7) . Prevention of the development of resistant strains through the proper use of antimicrobial agents in hospitals has thus become an important countermeasure against nosocomial infections.
From 2005 through 2008 we studied the annual trends in the antimicrobial susceptibility of clinical strains of P. aeruginosa isolated from respiratory specimens at Dokkyo Medical University Hospital. Susceptibility of these strains to various drugs with antipseudomonas activity was tested. We then calculated the amounts of antimicrobial agents used according to drug category in our hospital to examine the relation between drug usage and the annual trends in the antimicrobial susceptibility of P. aeruginosa.
Materials and Methods

Strains used in the study
We studied clinical strains of P. aeruginosa isolated from expectorated sputum, aspirated sputum, bronchial lavage fluid, and other respiratory specimens at Dokkyo Medical University Hospital between 2005 and 2008. Collection of clinical isolates was started in November of each year and was discontinued when about forty strains were obtained (up to April of the following year). If multiple strains were isolated from the same patient on different days, strains with similar antimicrobial susceptibility patterns were regarded as the same strain, and the initially isolated strain was studied. Strains with different antimicrobial susceptibility patterns were regarded as different strains.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by the microdilution method according to recommendations of the Clinical and Laboratory Standards Institute (8) . Susceptibility to the following 10 drugs with known titers was tested: ciprofloxacin, gentamicin, amikacin, arbekacin, piperacillin, sulbactam/cefoperazone, ceftazidime, imipenem, meropenem, and biapenem.
Detection of -lactamases
β-lactamase production was tested by the broth method using Nitrocefin (Kanto Chemical Co., Inc., Tokyo, Japan) as the reaction substrate as described in the instructions for use. For strains that had a minimal inhibitory concentration (MIC) of !32 μg/mL ceftazidime, metallo-β-lactamase production was confirmed by the disk diffusion method (SMA disk, Eiken Chemical Co., Ltd., Tokyo, Japan) (9).
Definition of Multidrug-resistant P. aeruginosa (MDRP)
MDRP was defined as strains that were resistant to imipenem (MIC !16 μg/mL), amikacin (MIC !32 μg/mL), and ciprofloxacin (MIC !4 μg/mL), respectively.
Abbreviation:
Relation between annual trends in antimicrobial use density (AUD) and annual trends in susceptibility rates according to clinical breakpoints for drugs
The AUD was defined as the daily dose of antimicrobials used per 1,000 patient-days as recommended by WHO. The AUD was calculated to compare the annual amounts of the following antimicrobials used at our hospital from 2005 through 2008: fluoroquinolones, aminoglycosides, penicillins, cephems, and carbapenems (10) . Because the defined daily doses of arbekacin and biapenem are not specified by WHO, the doses recommended in the package inserts (arbekacin, 0.4 mg; biapenem, 1.2 mg) were used. We also examined the relation between the AUD of the following representative antimicrobials and annual trends in susceptibility rates as defined by the clinical breakpoints (pneumonia and chronic respiratory tract infection) proposed by the Japanese Society of Chemotherapy: ciprofloxacin, amikacin, piperacillin, ceftazidime, imipenem, meropenem, and biapenem.
Statistical analysis
Statistical analysis was performed with the Mann-Whitney U test, and McNemar's exact test. P values of less than 0.05 were considered to indicate statistical significance. 
Results
Numbers of strains isolated from clinical specimens
Detection of -lactamases
The rate of β-lactamase production by the 150 isolated strains on the Nitrocefin test was 100%. However, no metallo-β-lactamase-producing strains were detected.
Detection rates of resistant strains
Of the 150 strains, none (0%) were MDRP, 37 (24.6%) were resistant to one drug (imipenem, 27 [18.0%], ciprofloxacin, 7 [4.6%], and amikacin, in 3 [2.0%]), 3 (2.0%) were resistant to two drugs (imipenem and ciprofloxacin), and 110 (73.3%) were not resistant to any of these drugs (Fig. 1) . 0 %) we r e r e s i s t a n t t o t wo d r u g s ( i mi p e n e m a n d c i p r o f l o x a c i n ) , a n d 1 1 0 ( 7 3 . 3 %) we r e n o t r e s i s t a n t t o a n y o f t h e s e d r u g s . MDRP d e n o t e s mu l t i d r u g -r e s i s t a n t P s e u d o mo n a s a e r u g i n o s a , I P M: i mi p en e m, AMK: a mi k a c i n a n d Annual trends in the antimicrobial susceptibility of P. aeruginosa isolated from respiratory specimens (Table 1A, 
Annual trends in susceptibility rates based on clinical breakpoints (pneumonia and chronic respiratory tract infection) (Tables 2 and 3)
The susceptibility rates based on the clinical breakpoints for pneumonia in 2005, 2006, 2007, and 2008 were as follows: ciprofloxacin, 88%, 97%, 94%, and 97%; biapenem, 68%, 72%, 88%, and 77%; meropenem, 70%, 63%, 88%, and 80%; imipenem, 58%, 72%, 86%, and 76%; ceftazidime 83%, 78%, 76%, and 77%; gentamicin, 65%, 56%, 94%, and 71%; and amikacin, 73%, 75%, 91%, and 74%, indicating relatively high susceptibility. In contrast, they were 5%, 9%, 15%, and 6% for piperacillin and 3%, 6%, 6%, and 3% for sulbactam/cefoperazone indicating low susceptibility (Table 2). The susceptibility rates based on the clinical breakpoints for chronic respiratory tract infection were generally similar to those for pneumonia ( Table 3) . Table 4 An n u a l T r e n d s i n S u s c e p t i b i l i t y Ra t e s o f P . A e r u g i n o s a a c c o r losporins increased significantly (p<0.01), and the susceptibility of P. aeruginosa to ceftazidime decreased slightly, but not significantly. In contrast, a decrease in the AUD of carbapenems was associated with a higher rate of susceptibility to imipenem. The AUD of fluoroquinolones was low (about 2). The rates of susceptibility to ciprofloxacin were high (about 95%). Figures 3 and 4 show the annual AUDs of carbapenems and cephalosporins, and the rates of susceptibility to imipenem, meropenem, biapenem, and ceftazidime according to the clinical breakpoints for pneumonia and chronic respiratory tract infection. The decrease in the AUD of carbapenems was associated with higher rates of susceptibility to these 3 carbapenems.
Comparison of annual trends in AUD according to antimicrobial type and susceptibility rates based on clinical breakpoints
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Comparison of the rates of resistance of P. aeruginosa to various antimicrobials Table 5 shows a comparison of the rates of crossresistance of P. aeruginosa to ciprofloxacin, amikacin, ceftazidime, imipenem, meropenem, and biapenem according to the clinical breakpoints for pneumonia proposed by the Japanese Society of Chemotherapy. The rate of resistance to ciprofloxacin was significantly lower than those of amikacin, ceftazidime, imipenem, meropenem, and biapenem. Except for ciprofloxacin, the rates of resistance did not differ significantly among any other drugs (data not shown).
Discussion
P. aeruginosa is a gram-negative bacillus that lives in natural habitats such as soil, rivers, and plants. The pathogenicity of P. aeruginosa is usually low. This organism rarely causes infections in healthy individuals, but it can cause nosocomial infections such as pneumonia and sepsis in immunocompromised hosts or in those with serious underlying diseases; such infections often do not respond to treatment. The natural resistance of P. aeruginosa to many antimicrobials is attributed to the low permeability of its outer membrane. Since 1990's, the rates of resistance of clinical isolates of P. aeruginosa to β-lactams, aminoglycosides, fluoroquinolones, and carbapenems have increased. In 2001, 89 (2.8%) of 3,233 strains of P. aeruginosa isolated at major university hospitals in Japan were reported to be MDRP. The rate of resistance ranged from 0.9% to 3.9%, depending on the region where P. aeruginosa was isolated (5). Among the 150 strains isolated from respiratory specimens from 2005 through 2008 in our study, none were MDRP, 2.0% were resistant to 2 of 3 drugs (imipenem, amikacin, and ciprofloxacin), and 24.6% were resistant to 1 of 3 drugs. In particular, 20.0% of the strains were resistant to imipenem, and 4.6% were resistant to ciprofloxacin. Antimicrobial resistance of P. aeruginosa can be caused by several factors, including reduced outer-membrane permeability due to decreased levels of porin protein D2 (11), increased drug efflux from bacterial cells via efflux pumps (12) , DNA gyrase and topoisomerase mutations (13, 14) , the production of modifying enzymes and metallo-β-lactamases (15) (16) (17) , and the involvement of multiple structural genes and regulatory genes (18) . Resistance of P. aeruginosa to carbapenems may be caused by impaired outer-membrane permeability and drug efflux systems. OprD, a porin protein existing on the outer membrane of P. aeruginosa, forms pores that are used for the intracellular uptake of basic amino acids and their peptides (19) . Carbapenems enter cells through these pores and are pumped out by efflux systems. The antibacterial activity of imipenem is decreased by reduced OprD expression, but it is minimally affected by the lack of drug efflux systems or by high expression of OprD. In contrast, the antibacterial activity of meropenem is altered by decreased OprD expression, as well as by the lack of drug efflux systems and high expression of OprD (11, 20, 21) . Increases or decreases in the usage of carbapenems may thus influence OprD expression or drug efflux systems of organism such as P. aeruginosa. During the 4-year period of this study, the use of fourthgeneration cephalosporins increased (16.2, 18.4, 28.0, and 23.0), while that of carbapenems decreased (25.7, 23.7, 10.9, and 12.5). These annual changes in the AUDs of drugs of different categories is most likely attributed to increased emphasis on educational activities designed to promote measures to prevent infection and multidrug-resistance and ensure the proper use of antimicrobials in hospitals. These factors probably contributed to the decreased usage of carbapenems. We assessed trends in the susceptibility rates of P. aeruginosa isolates obtained from respiratory specimens from 2005 through 2008 on the basis of MIC90/MIC50. Our results showed that susceptibility to carbapenems improved. Susceptibility rates based on the clinical breakpoints for pneumonia and chronic respiratory tract infection also improved. However, the susceptibility of P. aeruginosa to cephalosporins indicated a slight decrease. As influenced by the low usage of intravenous fluoroquinolones in our hospital, the rate of cross-resistance of P. aeruginosa to ciprofloxacin, according to the clinical breakpoints for pneumonia, was significantly lower than those of other antimicrobials. A close relation between the amount of antimicrobials used and the emergence of drug resistance is supported by the results of many studies. High usage of carbapenems has been reported to contribute to the emergence of MDRP (22, 23) , and reduced overall usage of antimicrobials decreases the rate of resistance of P. aeruginosa to β-lactams (24) . A significant decrease in AUD caused by restricting the use of carbapenems has been associated with the increased susceptibility and decreased resistance of P. aeruginosa (25) . Moreover, a decreased AUD of third-generation cephems is associated with a significant reduction in the detection rate of extended-spectrum, β-lactamase-producing Klebsiella pneumoniae (26) . In this study, we examined the relation between the annual changes in the susceptibility rates of P. aeruginosa isolates obtained from respiratory specimens at a university hospital during a 4-year period and annual trends in the overall usage of antimicrobials at the same hospital during the same period. Because of the low number of P. aeruginosa isolates (about forty strains of each year), there still remains uncertainty as to the results in this research. Further studies are needed to examine the relation between changes in the susceptibility rates of a large number of P. aeruginosa and the AUD of antimicrobial drugs over a longer period. A continuous understanding of trends in the resistance of P. aeruginosa and various other pathogens is essential for designing countermeasures against nosocomial infections, including the proper and effective use of antimicrobials.
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i n t s ( P n e u mo n i a ) . T h e d e c r e a s e i n t h e AUDs o f c a r b a p e n e ms wa s a s s o c i a t e d wi t h h i g h e r r a t e s o f s u s c e p t i b i l i t y t o i mi
i n t s ( Ch r o n i c r e s p i r a t o r y t r a c t i n f e c t i o n ) . T h e d e c r e a s e i n t h e AUDs o f c a r b a p e n e ms wa s a s s o c i a t e d wi t h h i g h e r r a t e s o f s u s c e p t i b i l i t y t o i mi p e n e m, me r o p e n e m a n d b i a p e n e m, wh e r e a s s u s c e p t i b i l i t y t o c e f t a z i d i me d e c r e a s e d a s s o c i a t e d wi t h t h e i n c r e a s e o f t h e AUD o f f o u r t h -g e n e r a t i o n c e p h a l o
Abbreviations: AUD: antimicrobial use density, MDRP: multidrug-resistant Pseudomonas aeruginosa
